BKHA
Fiscal year ends November Quarters are offset from the calendar — Q1 is Dec–Feb

Black Hawk Acquisition Corporation is a blank check company formed on September 28, 2023, to complete a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more target businesses. The company does not limit its search to a specific industry or geographic region and has no revenue or operating business other than identifying and evaluating acquisition candidates. On April 26, 2025, it entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. and BH Merger Sub, Inc., intending to consummate the transaction subject to customary closing conditions. The company completed its initial public offering on March 20, 2024, and holds proceeds in a trust account for the benefit of public shareholders. Its management team includes Kent Louis Kaufman, Jonathan Ginsberg, Daniel M. McCabe, and Terry W. Protto.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Shell Companies Homepage bhspac.com
Sector Financial Services IR page bhspac.com/investor-relations
Tags
blank check company, business combination, merger, acquisition, reorganization, share exchange, asset acquisition, recapitalization, Vesicor Therapeutics Inc., BH Merger Sub Inc.
Press page —

Metrics

Valuation  
Market cap $ 51.297M
Market cap (USD) $ 51.297M
P/E 39.47
PEG —
P/BV -10.89
P/S —
P/OCF -91.59
P/FCF -78.88
Dividend yield —
Turnover / mcap —
Returns  
ROE -34.6%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding —
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score -55.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023
Assets 23.878M 72.143M 263K
Net profit 1.33M 1.916M 0
Free cash flow -650.321K -553.665K —

Figure FY 2025 FY 2024 FY 2023
Share price 11.11 10.24 —
Price performance 12m 0.09 — —

Filed figures

Figure Nov 2023 Nov 2024 Nov 2025
Balance sheet detail
Cash and deposits (USD) 0.00 0.00 0.00
Intangible assets (USD) — — 5M
Cash flow detail
Operating cash flow (USD) — -553,665 -650,321
Change in payables (cash effect) (USD) — 64,125 240,885
Reported Apr 19, 2024 Feb 7, 2025 Mar 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On October 13, 2026, Black Hawk Acquisition Corporation (the “Company”) held an extraordinary general meeting of Shareholders (the “Extraordinary General Meeting”). The record date for shareholders entitled to notice of and to vote at the Extraordinary General Meeting was September 1, 2026. As of the record date, 4,153,577 ordinary shares were issued and outstanding and entitled to vote at the Extraordinary General Meeting. Of these shares, 3,211,516 shares, representing approximately 77.3% of the outstanding ordinary shares entitled to vote, were present by virtually or represented by proxy at the Extraordinary General Meeting, constituting a quorum.

At the Extraordinary General Meeting, shareholders voted on eight proposals, each of which is described in greater detail in the Company’s definitive proxy statement. The final voting results for each proposal are set forth below:

Proposal 1 – Business Combination Proposal

The Company’s shareholders approved, by ordinary resolution, the Business Combination Agreement, dated as of April 26, 2025 (as amended or supplemented from time to time, the “Business Combination Agreement”), by and among the Company, Vesicor Therapeutics, Inc.

On September 22, 2026, Black Hawk Acquisition Corporation, a Cayman Islands exempted company (“BKHA” or the “Company”), and Vesicor Therapeutics, Inc., a California corporation (“Vesicor”), entered into a series of financing and related agreements with Meteora Select Trading Opportunities Master, LP (“Meteora”) in connection with the Company’s previously announced business combination with Vesicor (the “Business Combination”). Pursuant to the Business Combination Agreement, dated April 26, 2025, by and among the Company, BH Merger Sub, Inc. and Vesicor (as amended or otherwise modified from time to time, the “Business Combination Agreement”), the Company will domesticate as a Delaware corporation and change its name to “Vesicor Therapeutics Holdings, Inc.” (“PubCo”), and Vesicor will become a wholly owned subsidiary of PubCo.

Forward Purchase Agreement

On September 22, 2026, the Company, Vesicor and Meteora entered into an OTC Equity Prepaid Forward Transaction confirmation (the “Forward Purchase Agreement”).

Prompts

Black Hawk Acquisition Corporation (ticker BKHA), listed in United States.

ETFs Holding Black Hawk Acquisition Corporation

ETF Weight in ETF Shares Market value As of
SPAQ 0.04% 2,857 $ 4,399.78 Jun 30, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
BKHA canonical Common share — US nasdaq 12.35 USD 2026-09-30
BKHAR Right — US nasdaq 1.58 USD 2026-09-30
BKHAU Unit — US nasdaq 12.50 USD 2026-09-30